4-Sep-2026
Treace Medical Concepts Reports Second Quarter 2026 Financial Results
Globe Newswire (Fri, 7-Aug 7:05 AM ET)
Did Treace Medical Concepts, Inc. Insiders Breach their Fiduciary Duties to Shareholders?
PRNewswire (Fri, 24-Jul 2:24 PM ET)
Treace to Report Second Quarter 2026 Financial Results on August 7, 2026
Globe Newswire (Fri, 24-Jul 7:05 AM ET)
Globe Newswire (Mon, 13-Jul 9:49 AM ET)
Globe Newswire (Thu, 18-Jun 7:05 AM ET)
Sidoti Events, LLC's June Small-Cap Virtual Conference
ACCESS Newswire (Tue, 16-Jun 10:00 AM ET)
Market Chameleon (Fri, 12-Jun 5:55 AM ET)
Treace to Present at the Sidoti Small Cap Conference
Globe Newswire (Thu, 11-Jun 4:05 PM ET)
Treace Medical Concepts Inc is a commercial-stage orthopaedic medical device company. It is focused on advancing the standard of care for the surgical management of bunion deformities. The company's patented Lapiplasty 3D Bunion Correction procedure is designed to reproducibly correct all planes of the bunion deformity and address the root cause of the bunion, while allowing patients to return to their active lives quickly. The company operates and manages its business as a single segment: designing, manufacturing, and marketing medical devices for surgeons, ambulatory surgery centers, and hospitals related to the surgical management of bunion and related midfoot deformities.
Treace Medical Concepts trades on the NASDAQ stock market under the symbol TMCI.
As of September 4, 2026, TMCI stock price declined to $4.81 with 207,879 million shares trading.
TMCI has a beta of 3.51, meaning it tends to be more sensitive to market movements. TMCI has a correlation of 0.23 to the broad based SPY ETF.
TMCI has a market cap of $312.82 million. This is considered a Small Cap stock.
Last quarter Treace Medical Concepts reported $45 million in Revenue and -$.24 earnings per share. This beat revenue expectation by $1 million and exceeded earnings estimates by $.06.
In the last 3 years, TMCI traded as high as $15.98 and as low as $1.17.
The top ETF exchange traded funds that TMCI belongs to (by Net Assets): VTI, VXF, SCHA, VHT, SCHB.
TMCI has underperformed the market in the last year with a return of -32.9%, while SPY returned +19.8%. This shows that you would have done better investing in the overall market (through SPY) over the last year than in TMCI shares. However, TMCI has outperformed the market in the last 3 month and 2 week periods, returning +30.4% and +10.8%, while SPY returned +2.0% and +0.6%, respectively. This indicates TMCI has been having a stronger performance recently.
TMCI support price is $4.62 and resistance is $5.14 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that TMCI shares will trade within this expected range on the day.
